| Reviewed human evidence | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected primary reports in osteoporosis: ACTIVE, its ACTIVExtend follow-up, and ATOM. The extension follows participants from ACTIVE rather than providing an independent replication.↗↗↗ Read the reviewed studies and limitations → | Four selected reports cover randomized trials in erythropoietic protoporphyria (EPP), an observational EPP cohort, combination treatment in vitiligo, and an exploratory stroke study. This is a selected overview, not a completed systematic review.↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.↗↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.↗↗↗ Read the reviewed studies and limitations → | Three selected reports cover a phase 2 dose-finding trial, the two phase 3 RECONNECT trials, and a safety analysis that reuses development-program participants. Other populations and formulations are outside this synthesis.↗↗↗ Read the reviewed studies and limitations → | Six selected reports include cagrilintide alone and the cagrilintide-semaglutide combination known as CagriSema. The later combination trials address different populations and questions from the earlier cagrilintide-alone study.↗↗↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected reports cover the randomized Barth syndrome study, follow-up of the same cohort, and a separate primary mitochondrial myopathy trial. They do not cover every indication or replace the product-specific regulatory record.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Two selected small studies examined delta sleep-inducing peptide (DSIP) in chronic insomnia. Their short observation periods and incompletely described formulations limit transfer to other preparations or uses.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two randomized placebo-controlled trials in type 2 diabetes: one short monotherapy trial and one large cardiovascular-outcomes trial.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected reports examine glucagon rescue formulations in diabetes. Nasal, intramuscular and ready-to-use subcutaneous products have different delivery contexts; related analogues and diagnostic uses require separate assessment.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.↗↗ Read the reviewed studies and limitations → | Two publications report adult chronic-constipation trials and a pediatric functional-constipation trial. They do not cover the full irritable-bowel-syndrome program or every currently labeled age group.↗↗ Read the reviewed studies and limitations → | A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.↗↗ Read the reviewed studies and limitations → | Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Two selected reports describe early development and a phase 2 trial of an antibody–peptide conjugate combining GIP-receptor antagonism with GLP-1-receptor agonism. Animal experiments and human trial results are separate evidence.↗↗ Read the reviewed studies and limitations → | Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected human reports measured naturally occurring MOTS-c during exercise studies or in patients with coronary endothelial dysfunction. None of these reports tested administering MOTS-c to people.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two randomized acromegaly trials: a short placebo-controlled study and a Phase 3 maintenance comparison in patients already responsive to somatostatin receptor ligands.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Two selected reports examine liver-fat changes during an extension study and histologic outcomes in a phase 2 trial. The extension continues an earlier participant cohort; it is not a separate randomized trial.↗↗ Read the reviewed studies and limitations → | One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.↗ Read the reviewed studies and limitations → | Three selected publications report four randomized phase 3 trials in adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.↗↗↗ Read the reviewed studies and limitations → | Three selected reports examine pramlintide alongside insulin in diabetes. Two are year-long adjunctive-treatment trials; the third evaluates an experimental automated insulin-and-pramlintide system and is not interchangeable with routine labeled treatment.↗↗↗ Read the reviewed studies and limitations → | Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.↗↗ Read the reviewed studies and limitations → | Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of sponsor-funded Phase 3 studies in rare genetic obesity syndromes: two small single-arm trials with withdrawal periods and one randomized trial followed by an open-label period.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.↗↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → | Three selected placebo-controlled trials examined intrathecal ziconotide for severe refractory pain. Intrathecal delivery and the studied populations are essential context; these are not general-use pain studies.↗↗↗ Read the reviewed studies and limitations → | No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage → |
|---|
| Trial phases at observation | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 1 selected record
- Phase 3: 1 selected record
7 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 2 selected records
- Phase 2: 1 selected record
14 of 16 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 8 selected records
- Phase 1: 3 selected records
- Phase 2: 2 selected records
0 of 13 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 6 selected records
0 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 4 selected records
- Phase 3: 3 selected records
- Phase 2: 1 selected record
0 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 3: 1 selected record
0 of 3 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 2 selected records
0 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 10 selected records
- Phase 3: 9 selected records
- Not applicable: 5 selected records
- Phase 2: 3 selected records
- Phase 1: 1 selected record
2 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 1 selected record
1 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 1 selected record
- Phase 3: 1 selected record
- Phase 4: 1 selected record
3 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 2 selected records
- Phase 3: 2 selected records
4 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 3 selected records
- Not applicable: 1 selected record
0 of 4 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 15 selected records
- Phase 3: 11 selected records
- Phase 1: 3 selected records
- Phase 4: 2 selected records
0 of 29 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 6 selected records
- Phase 4: 5 selected records
- Phase 3: 4 selected records
- Not applicable: 3 selected records
- Phase 1: 3 selected records
2 of 21 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 7 selected records
- Phase 2: 6 selected records
- Phase 3: 6 selected records
- Phase 4: 5 selected records
- Early Phase 1: 2 selected records
- Phase 1: 1 selected record
1 of 26 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 1 selected record
0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 2 selected records
- Phase 2: 1 selected record
0 of 3 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 3 selected records
- Phase 3: 3 selected records
- Phase 4: 2 selected records
- Not applicable: 1 selected record
- Phase 2: 1 selected record
1 of 11 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 13 selected records
- Phase 3: 9 selected records
- Phase 2: 5 selected records
- Phase 1: 2 selected records
- Not applicable: 1 selected record
0 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 10 selected records
- Phase 2: 7 selected records
- Phase 1: 1 selected record
0 of 16 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 20 selected records
- Phase 3: 10 selected records
- Not applicable: 2 selected records
- Phase 1: 2 selected records
1 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 10 selected records
- Phase 4: 7 selected records
- Phase 2: 4 selected records
- Phase 1: 3 selected records
1 of 25 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 3 selected records
- Phase 2: 2 selected records
- Phase 1: 1 selected record
0 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 2 selected records
- Phase 1: 1 selected record
- Phase 2: 1 selected record
- Phase 4: 1 selected record
6 of 11 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 7 selected records
- Phase 2: 2 selected records
0 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 3 selected records
- Phase 3: 2 selected records
- Phase 1: 1 selected record
0 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 1: 1 selected record
- Phase 3: 1 selected record
- Phase 4: 1 selected record
5 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 10 selected records
- Phase 3: 6 selected records
- Phase 2: 3 selected records
0 of 19 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 7 selected records
- Phase 3: 6 selected records
- Phase 4: 5 selected records
- Phase 1: 3 selected records
- Not applicable: 2 selected records
- Early Phase 1: 1 selected record
0 of 22 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 9 selected records
- Phase 3: 5 selected records
- Phase 4: 2 selected records
- Phase 1: 1 selected record
0 of 16 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 9 selected records
- Phase 1: 4 selected records
- Phase 2: 4 selected records
0 of 17 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 2 selected records
- Not applicable: 1 selected record
47 of 50 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 3 selected records
- Phase 1: 2 selected records
- Early Phase 1: 1 selected record
1 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 6 selected records
- Not applicable: 5 selected records
- Early Phase 1: 4 selected records
- Phase 2: 3 selected records
- Phase 3: 3 selected records
- Phase 1: 2 selected records
5 of 27 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 9 selected records
- Phase 4: 8 selected records
- Phase 2: 6 selected records
- Not applicable: 1 selected record
2 of 26 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 5 selected records
- Phase 1: 3 selected records
0 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 3 selected records
- Not applicable: 1 selected record
27 of 31 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 2 selected records
- Phase 2: 2 selected records
- Phase 3: 2 selected records
- Not applicable: 1 selected record
0 of 5 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 14 selected records
- Phase 3: 10 selected records
- Phase 1: 3 selected records
- Phase 4: 2 selected records
- Not applicable: 1 selected record
0 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 1 selected record
0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 11 selected records
- Phase 2: 5 selected records
- Phase 4: 2 selected records
- Phase 1: 1 selected record
2 of 19 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 2 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 1 selected record
0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 2 selected records
11 of 13 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 6 selected records
- Phase 1: 2 selected records
0 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 30 selected records
- Phase 3: 9 selected records
- Phase 1: 8 selected records
- Not applicable: 5 selected records
- Phase 4: 4 selected records
66 of 117 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 3: 2 selected records
- Not applicable: 1 selected record
10 of 15 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 8 selected records
- Phase 3: 4 selected records
- Not applicable: 2 selected records
- Phase 1: 2 selected records
- Phase 2: 2 selected records
64 of 82 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 1 selected record
- Phase 4: 1 selected record
4 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 1 selected record
- Phase 2: 1 selected record
0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 20 selected records
- Phase 1: 7 selected records
- Phase 3: 4 selected records
- Phase 4: 1 selected record
0 of 27 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 7 selected records
- Phase 1: 5 selected records
- Phase 2: 1 selected record
6 of 19 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 6 selected records
- Not applicable: 4 selected records
- Phase 3: 3 selected records
- Phase 4: 1 selected record
4 of 17 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 5 selected records
- Not applicable: 3 selected records
- Phase 1: 3 selected records
- Phase 3: 1 selected record
1 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 18 selected records
- Phase 3: 3 selected records
- Phase 1: 2 selected records
- Phase 4: 2 selected records
- Not applicable: 1 selected record
1 of 25 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 1 selected record
- Phase 2: 1 selected record
0 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 4 selected records
- Phase 2: 2 selected records
- Phase 4: 1 selected record
0 of 7 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 1 selected record
- Phase 1: 1 selected record
- Phase 2: 1 selected record
0 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 12 selected records
- Phase 3: 8 selected records
- Phase 1: 7 selected records
- Phase 4: 3 selected records
- Not applicable: 1 selected record
0 of 25 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 3: 1 selected record
- Phase 4: 1 selected record
53 of 57 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 19 selected records
- Phase 1: 4 selected records
- Phase 4: 2 selected records
0 of 25 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 4: 16 selected records
- Phase 2: 7 selected records
- Phase 3: 3 selected records
- Not applicable: 2 selected records
0 of 27 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 2 selected records
2 of 4 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 17 selected records
- Phase 1: 8 selected records
- Phase 3: 3 selected records
- Phase 4: 3 selected records
1 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 9 selected records
- Phase 3: 7 selected records
- Phase 1: 6 selected records
- Phase 4: 1 selected record
2 of 23 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 8 selected records
- Phase 3: 5 selected records
- Phase 1: 1 selected record
0 of 14 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 1: 1 selected record
- Phase 3: 1 selected record
2 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 3 selected records
- Phase 3: 3 selected records
- Phase 1: 2 selected records
2 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 3 selected records
- Phase 3: 1 selected record
8 of 12 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 1 selected record
- Phase 3: 1 selected record
3 of 5 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 7 selected records
- Phase 2: 1 selected record
1 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 4 selected records
- Phase 3: 1 selected record
0 of 5 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 3 selected records
- Phase 2: 3 selected records
- Phase 3: 3 selected records
- Not applicable: 2 selected records
- Phase 4: 2 selected records
2 of 12 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 22 selected records
- Phase 2: 19 selected records
- Phase 1: 12 selected records
- Phase 4: 10 selected records
- Not applicable: 4 selected records
76 of 140 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 3 selected records
- Phase 2: 2 selected records
- Phase 4: 1 selected record
8 of 14 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 7 selected records
- Phase 1: 4 selected records
3 of 14 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 1: 1 selected record
- Phase 2: 1 selected record
0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 17 selected records
- Phase 2: 7 selected records
- Phase 1: 5 selected records
- Phase 4: 2 selected records
- Early Phase 1: 1 selected record
0 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 4 selected records
- Phase 4: 3 selected records
- Phase 2: 2 selected records
64 of 73 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 11 selected records
- Phase 2: 9 selected records
- Phase 4: 6 selected records
- Not applicable: 5 selected records
- Phase 1: 1 selected record
1 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 2 selected records
- Phase 1: 1 selected record
- Phase 3: 1 selected record
7 of 11 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 6 selected records
- Phase 1: 2 selected records
0 of 7 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Not applicable: 5 selected records
- Phase 2: 1 selected record
- Phase 3: 1 selected record
0 of 7 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 9 selected records
- Phase 3: 3 selected records
- Phase 4: 3 selected records
- Phase 1: 2 selected records
- Not applicable: 1 selected record
1 of 18 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 4 selected records
- Phase 3: 4 selected records
0 of 7 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 22 selected records
- Phase 3: 13 selected records
- Phase 4: 13 selected records
- Phase 1: 7 selected records
- Early Phase 1: 2 selected records
- Not applicable: 2 selected records
54 of 108 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 11 selected records
- Not applicable: 6 selected records
- Phase 2: 6 selected records
- Phase 4: 4 selected records
- Phase 1: 1 selected record
3 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 2 selected records
- Phase 2: 1 selected record
0 of 3 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 9 selected records
- Phase 3: 9 selected records
- Phase 4: 9 selected records
- Not applicable: 4 selected records
- Phase 1: 3 selected records
0 of 30 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 3 selected records
- Phase 2: 2 selected records
- Phase 1: 1 selected record
0 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 2: 4 selected records
- Phase 3: 1 selected record
5 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | No phase values available in this selected collection. 4 of 4 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → | - Phase 3: 7 selected records
- Phase 2: 4 selected records
- Phase 1: 2 selected records
1 of 11 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations → |
|---|
| Regulatory records | No FDA approval reported; studied only in cells and animals↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Tymlos for osteoporosis↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 16 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Scenesse for erythropoietic protoporphyria↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 11 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Tanzeum; discontinued↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; FDA advised against adding it to the compounding list↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; studied in clinical trials↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Angiomax and generics as an anticoagulant during coronary procedures↗↗ - 14 connected Drugs@FDA applications
- 4 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Vyleesi for HSDD in premenopausal women↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 2 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Miacalcin for Paget’s disease, high blood calcium and osteoporosis↗↗ - 15 connected Drugs@FDA applications
- 8 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Kyprolis for relapsed or refractory multiple myeloma↗↗ - 6 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied in clinical trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Cetrotide for use in controlled ovarian stimulation↗↗ - 7 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; studied in clinical trials↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; named as an unapproved new drug in a federal enforcement case↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; studied in clinical trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Dalvance for acute bacterial skin infections↗↗ - 6 connected Drugs@FDA applications
- 4 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Cubicin RF for skin infections and S. aureus bloodstream infections↗↗ - 32 connected Drugs@FDA applications
- 10 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Zegalogue for severe low blood sugar; discontinued↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Firmagon for advanced prostate cancer↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as DDAVP for diabetes insipidus and bedwetting↗↗ - 38 connected Drugs@FDA applications
- 13 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Korsuva for kidney-disease itching in adults on hemodialysis↗↗ - 2 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; FDA has no human exposure data for it↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Trulicity↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 39 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied in clinical trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Forzinity under accelerated approval for Barth syndrome↗↗ - 0 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; under FDA review for pharmacy compounding↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Fuzeon for HIV-1; discontinued↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Integrilin and generics for acute coronary syndrome and PCI↗↗ - 15 connected Drugs@FDA applications
- 4 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Parsabiv for secondary hyperparathyroidism on hemodialysis↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Byetta, Bydureon and generic exenatide↗↗↗↗↗ - 5 connected Drugs@FDA applications
- 11 Federal Register documents
- 5 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied as a gene therapy in small trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied only in cells and animals↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as NETSPOT for PET imaging of neuroendocrine tumors↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation↗↗ - 8 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; under FDA review for pharmacy compounding by non-injectable routes↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Copaxone for relapsing multiple sclerosis↗↗ - 11 connected Drugs@FDA applications
- 3 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Gvoke, Baqsimi and other glucagon products↗↗↗↗ - 10 connected Drugs@FDA applications
- 16 Federal Register documents
- 2 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Factrel and Lutrepulse; discontinued↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis↗↗ - 2 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Supprelin LA for central precocious puberty↗↗ - 3 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied only in the laboratory↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Firazyr for acute attacks of hereditary angioedema↗↗ - 11 connected Drugs@FDA applications
- 4 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied only in cells and animals↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Langlara↗↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 5 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; named as an unapproved new drug in a federal enforcement case↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; on FDA’s compounding safety-risk list (category 2)↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Somatuline Depot and other lanreotide products↗↗↗↗ - 4 connected Drugs@FDA applications
- 2 Federal Register documents
- 3 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; studied in clinical trials↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗ - 25 connected Drugs@FDA applications
- 19 Federal Register documents
- 17 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Linzess↗↗ - 4 connected Drugs@FDA applications
- 4 Federal Register documents
- 29 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Victoza, Saxenda and generic versions↗↗↗↗ - 13 connected Drugs@FDA applications
- 13 Federal Register documents
- 2 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Adlyxin and in Soliqua 100/33↗↗↗ - 1 connected Drugs@FDA applications
- 3 Federal Register documents
- 20 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; on FDA’s compounding safety-risk list↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors↗↗ - 3 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | China: approval reported by local government sources↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Increlex for severe primary IGF-1 deficiency in children↗↗ - 1 connected Drugs@FDA applications
- 4 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; on FDA’s compounding safety-risk list↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Myalept for generalized lipodystrophy↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Aphexda for stem cell mobilization in multiple myeloma↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Synarel for central precocious puberty and endometriosis↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA approval withdrawn in 2020 after the product left the market↗↗ - 1 connected Drugs@FDA applications
- 5 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Sandostatin and other octreotide products↗↗↗↗↗ - 27 connected Drugs@FDA applications
- 11 Federal Register documents
- 2 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Foundayo for weight reduction in adults↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Pitocin for labor and bleeding after birth↗↗ - 8 connected Drugs@FDA applications
- 22 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Yorvipath for hypoparathyroidism in adults↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Signifor for Cushing’s disease↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; FDA has no human exposure data for it↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Empaveli for PNH and two complement-driven kidney diseases↗↗ - 2 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA approval withdrawn in 2019 at the company’s request, after a 2013 recall↗↗ - 1 connected Drugs@FDA applications
- 3 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Trulance↗↗ - 1 connected Drugs@FDA applications
- 3 Federal Register documents
- 14 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Symlin↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 11 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Mimrylo for erythrocytosis in polycythemia vera↗↗ - 1 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as ChiRhoStim for pancreatic and gastrinoma testing↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ - 5 connected Drugs@FDA applications
- 13 Federal Register documents
- 19 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗ - 2 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Imcivree for specific rare causes of obesity↗↗ - 1 connected Drugs@FDA applications
- 4 Federal Register documents
- 10 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied only in cells and animals↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not an FDA-approved drug↗ - 0 connected Drugs@FDA applications
- 1 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Gattex for short bowel syndrome↗↗ - 1 connected Drugs@FDA applications
- 3 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Forteo and other teriparatide products↗↗↗↗↗↗ - 7 connected Drugs@FDA applications
- 6 Federal Register documents
- 9 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Terlivaz for hepatorenal syndrome↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Egrifta for HIV-associated abdominal fat↗↗ - 1 connected Drugs@FDA applications
- 3 Federal Register documents
- 9 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied in clinical trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported; studied in clinical trials↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | Not FDA-approved; FDA advised against adding it to the compounding list↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | No FDA approval reported↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Mounjaro and Zepbound↗↗↗ - 2 connected Drugs@FDA applications
- 8 Federal Register documents
- 22 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Trelstar for advanced prostate cancer↗↗ - 4 connected Drugs@FDA applications
- 3 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Daybue for Rett syndrome↗↗ - 2 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Vasostrict for vasodilatory shock↗↗ - 14 connected Drugs@FDA applications
- 9 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | In clinical trials; not FDA-approved↗↗↗ - 0 connected Drugs@FDA applications
- 0 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Voxzogo under accelerated approval for achondroplasia↗↗ - 1 connected Drugs@FDA applications
- 5 Federal Register documents
- 7 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Prialt for severe chronic pain↗↗ - 1 connected Drugs@FDA applications
- 1 Federal Register documents
- 6 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → | FDA-approved as Zilbrysq for generalized myasthenia gravis↗↗ - 1 connected Drugs@FDA applications
- 2 Federal Register documents
- 0 DailyMed label versions
Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections → |
|---|
| Coverage gaps | No selected records in: Clinical trials, Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How do fracture outcomes and harms compare with other treatments over longer follow-up and in populations outside these selected trials?↗↗↗
- Does the bone-density improvement observed in ATOM translate into fewer fractures in men?↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How durable are benefits and harms in broader EPP populations, including those underrepresented in the trials?↗↗↗↗
- What do controlled studies establish in indications beyond EPP, and how do combination treatments affect attribution?↗↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - How durable are effects after treatment ends, and what do longer studies show about serious harms?↗↗↗↗
- How do results differ by formulation, population, attrition and the analysis of missing outcomes?↗↗↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Do adequately powered controlled human trials reproduce any claimed benefit and characterize harms over meaningful follow-up?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How do the magnitude of symptom changes, treatment discontinuation and patient preferences affect interpretation?↗↗↗
- Which longer-term harms and populations remain inadequately characterized?↗↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - Do larger and longer trials confirm durability, characterize uncommon harms, and show outcomes after treatment stops?↗
- How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. - Which findings apply to the exact molecular form and formulation being discussed?↗↗
- Do controlled studies demonstrate patient-important benefits and adequately assess longer-term harms?↗↗
Inspect coverage and missing fields → | No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - What do longer-term studies establish for populations and outcomes outside these three selected reports?↗↗↗
- How do later trial analyses relate to their original cohorts, and which findings have independent replication?↗↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Which confirmatory results establish clinical benefit in the Barth syndrome population?↗↗↗
- How do study population, attrition and the absence of a control group affect the extension findings?↗↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. - Are the preparations and study populations sufficiently comparable to combine these reports?↗↗
- Do larger, longer randomized trials reproduce clinically meaningful sleep improvements?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. - Which translated or related reports describe the same participants?↗↗
- Do controlled studies assess patient-important outcomes and adequately report adverse events?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Which populations, if any, have durable patient-important benefits beyond glycemic control, and how do outcomes change after treatment discontinuation?↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. - Which outcomes are supported by adequately controlled studies of a clearly identified GHK-Cu formulation?↗↗↗
- How do route, co-ingredients, study size, and follow-up limit what can be concluded about benefits and harms?↗↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do current product labels distinguish rescue and diagnostic uses and age-specific indications?↗↗↗
- What do larger real-world studies establish about failures, harms and untrained-caregiver use?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Literature metadata, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Are there adequately controlled studies for proposed uses outside postoperative bowel recovery?↗↗
- How do route, formulation and follow-up affect what can be concluded about harms?↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do formulation, indication and prior-treatment differences affect applicability?↗↗↗
- What do complete trial reports and current labels add about harms and longer follow-up?↗↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do the compared approaches affect long-term patient-important outcomes, harms, and treatment persistence beyond the reviewed follow-up windows?↗↗
Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - What additional trials address irritable bowel syndrome and other age groups?↗↗
- How do current regulatory labels and longer follow-up refine the safety assessment?↗↗
Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do benefits and harms vary in lower-risk populations, after discontinuation, and over follow-up beyond the reviewed trials?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How do the monotherapy and fixed-combination regulatory records differ?↗↗
- What do the broader diabetes program and subsequent Parkinson trials establish?↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - What do full trial reports establish about attrition, estimands and discontinuation?↗↗
- What do subsequent trials and jurisdiction-specific agency records establish?↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - How do dated regulatory decisions differ by jurisdiction and indication?↗↗↗↗
- What do full reports establish about missing outcomes, uncommon harms and durability?↗↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. - What evidence directly evaluates administered MOTS-c in humans, separately from exercise and endogenous biomarker studies?↗↗↗
- How do assay methods, confounding and population differences affect observed associations?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do long-term symptoms, clinical outcomes, treatment burden, and harms compare in broader acromegaly populations not selected through a responder run-in?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. - How do the original trial and selected extension differ in participant retention and outcome analysis?↗↗
- What do full reports establish about missing outcomes, sustained histologic changes and longer-term clinical events?↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - What do larger, longer controlled trials establish about sustained weight changes and uncommon adverse events?↗
- Do head-to-head trials support any comparative benefit or tolerability claim?↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - What do current labels establish about pediatric restrictions and serious diarrhea?↗↗↗
- How durable are outcomes beyond the randomized treatment periods?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - What do the current label and complete trial reports establish about severe hypoglycemia and discontinuation?↗↗↗
- Can longer studies reproduce the automated-delivery findings and assess patient-important outcomes?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Do Phase 3 trials confirm durability, rare harms, and clinically important outcomes across more diverse populations?↗↗
- How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. - Can adequately randomized, masked studies reproduce the reported functional effects?↗↗
- What do complete reports establish about missing outcomes, concomitant care and safety?↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How durable are benefits and harms across each genetic subgroup, and which baseline features predict response in these exceptionally small populations?↗↗
Inspect coverage and missing fields → | No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. - Do Phase 3 trials confirm durable clinical outcomes, clarify fibrosis effects, and characterize harms across broader populations?↗↗
- How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - How do fracture outcomes, harms, and persistence compare across broader osteoporosis populations and after the reviewed treatment windows?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - Do the imaging changes translate into durable clinical benefits, and what are the longer-term effects in the studied population?↗↗
Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. - What are the durability, post-discontinuation outcomes, and uncommon harms across broader populations and longer follow-up?↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. - What do current regulatory warnings specify about psychiatric and neurological risks?↗↗↗
- How do longer observational reports address durability, discontinuation and uncommon harms?↗↗↗
Inspect coverage and missing fields → | No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields → |
|---|
| Review and check dates | Status sources checked through: Not available. Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: September 14, 2026. Review source snapshots checked: September 14, 2026. Integrity checked: September 14, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence reviewed through: August 18, 2026. Review source snapshots checked: August 18, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 29, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: Not available. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: Not available. Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 16, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 18, 2026. Review source snapshots checked: August 18, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 20, 2026. Review source snapshots checked: September 20, 2026. Integrity checked: September 20, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: August 14, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: November 14, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. | Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots →These dates do not imply continuous monitoring. | Status sources checked through: November 15, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring. |
|---|